PML/RARA Qualitative Gene Fusion (bcr1 & bcr3) in UAE | 700 AED | DHA Licensed

Executive Summary & Core Metrics

✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing. Reverse-transcription quantitative PCR (RT‑qPCR) with bcr1 and bcr3 isoform detection, validated on modern LC‑MS/MS‑confirmed standards.

🚑 Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. For peripheral blood draws, please visit our partner clinics.

📞 Clinical Guidance: Telephonic Post‑Test Clinical Guidance in result interpretation by DHA‑licensed specialists.

📄 Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The PML/RARA qualitative gene fusion test detects the t(15;17) translocation hallmark of acute promyelocytic leukaemia (APL). Using reverse‑transcription real‑time PCR (RT‑qPCR), this assay identifies both bcr1 (long) and bcr3 (short) isoforms with exceptional sensitivity, guiding rapid targeted therapy.

This test is the gold standard for confirming APL and monitoring measurable residual disease. Results are reported as positive or negative for the fusion transcript.

Feature	Our Test (ISO Certified)	Alternative Labs
Methodology	RT‑qPCR with bcr1 & bcr3 dual‑target specificity (LC‑MS/MS‑validated)	Conventional nested PCR; possible single isoform detection
Turnaround Time	2–3 days (weekend processing available)	5–7 days standard
Sample Collection	Hospital‑based bone marrow aspirate or peripheral blood draw; temperature‑controlled transport	Variable; no dedicated cold chain

Physician Insight & Safety Protocols

“Molecular detection of PML/RARA fusion provides definitive confirmation of APL, especially in cases where cytogenetic analysis is inconclusive. Integrating this test with imaging findings (e.g., MRI for extramedullary involvement) and coagulation profiles ensures comprehensive patient management. Early identification of the t(15;17) translocation directly impacts treatment decisions, including the timely use of all‑trans retinoic acid.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011

Advisory: Sample Integrity & Clinical Precautions

Proper sample handling is critical. Bone marrow aspirates must be collected under sterile conditions by experienced clinicians. Peripheral blood specimens must be drawn into EDTA tubes and transported immediately at 2–8°C. Hemolysed or clotted samples will be rejected to ensure diagnostic accuracy. Patients on anticoagulant therapy should inform their physician prior to collection.

Exclusion Criteria & Emergency Red Flags

Exclusion criteria: Active uncontrolled systemic infection or severe bleeding diathesis may require stabilisation before bone marrow aspiration. For peripheral blood draw, contraindications are minimal; however, patients with severe coagulopathy should be managed hospital‑based.
ER Red Flags: If you experience spontaneous bruising, gum bleeding, prolonged bleeding after minor cuts, fever, or severe fatigue, seek immediate emergency care — these may indicate APL‑associated coagulopathy.
Sample rejection: Specimens not transported immediately at 2–8°C, hemolysed samples, or clotted bone marrow will be rejected; a repeat collection will be scheduled at no extra logistic cost.

Patient FAQ & Clinical Guidance

1. What is the PML/RARA qualitative gene fusion test, and how does it help diagnose APL?

This test detects the abnormal PML/RARA gene fusion caused by t(15;17) translocation, which is the definitive molecular marker for acute promyelocytic leukaemia (APL). A positive result, with 99.9% specificity, directly enables immediate targeted therapy with retinoic acid and improves survival outcomes.

2. How is the test performed, and where should I go for sample collection?

Sample collection is performed exclusively at a hospital facility. You will need a bone marrow aspirate or peripheral blood draw by trained medical staff. The specimen is immediately placed in a temperature‑controlled container and rushed to our ISO 9001:2015 lab for RT‑qPCR analysis. Home phlebotomy is not available for this test due to safety requirements.

3. Will my health insurance cover this test, and how can I confirm?

Most UAE insurance plans cover this test when prescribed by a DHA‑licensed haematologist or oncologist. Send your prescription and insurance card via WhatsApp to +971 54 548 8731 for real‑time direct billing verification.

UAE Regulatory & Data Privacy Adherence

This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access‑controlled, and processed strictly for clinical diagnostic purposes. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Your health information is protected under UAE law.

Clinical & Logistical Metadata

Test Name	PML/RARA Qualitative Gene Fusion (bcr1 & bcr3)
Price (AED)	700
Turnaround Time	2–3 days
Sample Type / Matrix	Bone marrow aspirate or peripheral blood (EDTA)
Methodology Used	Reverse‑transcription quantitative PCR (RT‑qPCR) with bcr1 and bcr3 isoform detection
ICD-10-CM Code	C92.40 (Acute promyelocytic leukemia, not having achieved remission)
LOINC Code	92895-0 (PML/RARA fusion transcript [Presence] in Blood or Bone marrow by NAA with probe detection)
DHA Facility License & Laboratory Address	License 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE